Press Releases

Market Overview

The Australia pharmaceutical market is growing steadily, driven by the Pharmaceutical Benefits Scheme (PBS) expanding access to high-cost oncology biologics, a rapidly aging population, and rising government support. The market size increased from USD 25.3 Billion in 2025 to USD 26.2 Billion in 2026 and is projected to reach USD 31.9 Billion by 2034, registering a compound annual growth rate (CAGR) of 2.50% during 2026-2034. Antineoplastic and immunomodulating agents lead therapeutic classes at 18.6%, generics hold 57.4% of drug types, and Australia Capital Territory & New South Wales commands 35.8% of the market in 2025.

Request a Sample Report for In-Depth Market Insights: https://www.imarcgroup.com/australia-pharmaceutical-market/requestsample

Market Summary

• Antineoplastic and immunomodulating agents command 18.6% of the market by therapeutic class in 2025, reflecting premium pricing, with PBS spending on these agents averaging AUD 259 per person annually and accounting for around one third of PBS expenditure.
• Generic drugs hold the largest share at 57.4% of drug types in 2025, anchored by PBS price disclosure policies that reward generic substitution, with price reductions of approximately 31% when the first generic or biosimilar enters a medicine class.
• Prescription drugs dominate at 72.9% of the prescription type segment in 2025, as the PBS subsidy model channels most drug spend through physician scripts, complex biologic therapies, and strict authority requirements for high-cost medicines.
• Digital prescribing is reshaping distribution, with more than 219 million electronic prescriptions issued since 2020 by over 85,000 prescribers, while e-pharmacies are growing the fastest among distribution channels and 60-day dispensing is broadening access.
• Biosimilar adoption is accelerating under government uptake drivers, moderating expenditure on high-value biologics, while government grants stimulate onshore manufacturing of antimicrobials, injectables, and mRNA vaccines to reduce reliance on imported active pharmaceutical ingredients.
• The market is segmented by therapeutic class, drug type (branded, generic), prescription type (Rx, OTC), and region across five Australian regions, with forecasts for 2026-2034, and Australia Capital Territory & New South Wales leads regionally at 35.8%.

Market Growth Drivers

Aging Population and Rising Chronic Disease Burden

The aging population is a primary driver of the Australia pharmaceutical market growth. According to the Australian Bureau of Statistics, the number of Australians aged 85 and older is expected to double by 2042, surpassing 1 million people. As the population ages, demand for pharmaceuticals is expected to grow rapidly, as older Australians need multiple medications to manage various health conditions. Cancer incidence is also rising, with Australia registering over 165,000 new cancer diagnoses annually, with diagnosis rates outpacing population growth due to an aging demographic profile, supporting strong demand for oncology therapies and chronic disease medicines.

Commonwealth Budget Healthcare Investment and PBS Expansion

Federal healthcare investment is directly expanding pharmaceutical demand. The Budget allocated AUD 3.2 billion toward cheaper medicines in 2025-26, supporting reforms that improve affordability and access for households. An AUD 7.9 billion investment also targets universal bulk-billing coverage for 9 in 10 GP visits by 2030, expanding the volume of consultations that generate pharmaceutical prescriptions. The PBS reimbursement model, supported by price disclosure mechanisms, biosimilar uptake, and cost-sharing arrangements, is enabling more innovative treatments to be listed while managing net expenditure growth, with expanding specialist hospital capacity adding demand for high-cost injectable biologics, oncology infusions, and critical-care medicines.

TGA Regulatory Modernization and Digital Health Integration

Regulatory modernization is enabling faster drug launches. Priority-review pathways for novel biologics and rolling submissions for rare-disease therapies are shortening regulatory lead times, enabling faster commercialization of high-value medicines. In February 2025, the Therapeutic Goods Administration approved Alvotech and Cipla’s Uteknix, a biosimilar to Stelara (ustekinumab), and in April 2025 it approved Sandoz’s Tyruko, a biosimilar of Tysabri (natalizumab). At the same time, e-prescription legislation, mobile health apps, and telehealth consultations are reducing geographic barriers to pharmaceutical access, supporting broader patient reach across metropolitan and regional areas, and shortening the path from approval to patient access.

Porter’s Five Forces Analysis

Competitive Rivalry: Moderate to High

• Multinational originators such as AbbVie, Amgen, and AstraZeneca are competing on PBS listings, evidence generation, and portfolio depth.
• Generic and biosimilar entry is intensifying price competition as PBS price disclosure reduces prices.
• Brand strategy and new registrations, including Amgen’s denosumab registrations, are being used to preempt biosimilar competition.

Supplier Power: Moderate to High

• Heavy dependence on imported active pharmaceutical ingredients is exposing sponsors to currency volatility and geopolitical supply disruptions.
• Extended procurement lead times during global demand surges are adding supply chain risk.
• Onshore manufacturing grants and investments are gradually improving domestic supply options.

Buyer Power: High

• The government, through the PBS and PBAC, is the dominant payer and sets prices and listing conditions.
• Price disclosure triggers automatic subsidy reductions as competition intensifies.
• Hospitals and pharmacies influence demand through formulary choices and dispensing channels.

Threat of Substitutes: Moderate

• Generics and biosimilars substitute for originator brands once entry occurs.
• OTC medicines provide alternatives for minor and lifestyle conditions.
• Novel biologics and targeted therapies are limiting substitution in oncology and specialty care.

Threat of New Entrants: Low to Moderate

• TGA registration, PBAC cost-effectiveness standards, and multi-stage submissions are raising entry barriers.
• New affiliate launches, such as Neuraxpharm Australia, show sponsors still enter through Sydney.
• Domestic manufacturing investment and generics partnerships are opening routes for local and regional entrants.

Market Segmentation

Therapeutic Class Insights

• Alimentary Tract and Metabolism
• Blood and Blood Forming Organs
• Cardiovascular System
• Dermatologicals
• Genito Urinary System and Sex Hormones
• Systemic Hormonal Preparations
• Anti-infectives for Systemic Use
• Antineoplastic and Immunomodulating Agents
• Musculoskeletal System
• Nervous System
• Antiparasitic Products, Insecticides, and Repellents
• Respiratory System, Sensory Organs
• Others

Drug Type Insights

• Branded
• Generic

Prescription Type Insights

• Prescription Drugs (Rx)
• OTC Drugs

Regional Insights

• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

Regional Analysis

Australia Capital Territory & New South Wales: Australia Capital Territory & New South Wales is the dominant pharmaceutical region, holding a 35.8% share in 2025, anchored by Sydney’s concentration of specialist hospitals, the operational headquarters of major multinationals, and the ACT’s high government healthcare expenditure per capita. The region’s appeal for new entrants is shown by Neuraxpharm’s launch of its Australian affiliate, with Sydney as its operational center, in July 2025.

Victoria & Tasmania: Victoria is Australia’s second-largest pharmaceutical market, hosting significant pharmaceutical manufacturing infrastructure and clinical trial activity. Early-stage drug discovery is also active, with Race Oncology identifying 39 molecular candidates for FTO-targeting compounds at Monash University’s Fragment Platform in November 2024, supporting long-term pipeline and market demand.

Queensland: Queensland is expanding its pharmaceutical market through state-level pharmacist prescribing pilots that broaden primary care access and shift chronic-disease maintenance prescriptions into community pharmacy settings. A rapidly growing population and above-average rates of lifestyle-related chronic disease, including type 2 diabetes, cardiovascular conditions, and respiratory disease, are generating structural demand growth.

Northern Territory & Southern Australia: The Northern Territory presents distinctive challenges, including geographically dispersed populations, a high proportion of First Nations communities with elevated chronic disease burden, and logistics constraints for temperature-sensitive medicines in remote settings, and it has the lowest script volume and per-capita expenditure among states and territories. Southern Australia’s tertiary hospital network and urban demand are driving moderate regional growth.

Western Australia: Western Australia is driven by Perth’s growing tertiary care infrastructure, above-average state healthcare expenditure underpinned by mining-sector economic strength, and rising private health insurance coverage among higher-income residents. The state’s population is growing faster than the national average, and expanding specialist care capacity is generating PBS-linked prescription demand.

Competitive Landscape

The Australia pharmaceutical market is shaped by a concentrated group of multinational pharmaceutical corporations competing on PBS reimbursement expertise, pharmacoeconomic evidence generation, and supply chain resilience. AbbVie maintains a strong PBS position in adalimumab and is relocating its Sydney headquarters in late 2026, Amgen secured five new denosumab brand registrations in November 2024 to preempt biosimilar competition, and AstraZeneca has added PBS listings for chronic obstructive pulmonary disease. Detailed profiles of major companies are included in the full report.

Key players include:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• CSL Limited
• Eli Lilly Australia Pty Ltd
• GSK plc
• Merck KGaA
• Novartis Pharmaceuticals Australia Pty Ltd.
• Pfizer Australia Pty Ltd.
• Roche Australia
• Sanofi

Recent Industry Developments

November 2026: Mayne Pharma reports growth in women's health prescriptions and progress in manufacturing. Australian pharmaceutical company Mayne Pharma reported first-quarter FY2027 revenue of AUD 95.7 million for the three months ended 30 September 2026. Its women's health portfolio recorded prescription growth across BIJUVA, IMVEXXY and NEXTSTELLIS, while its DistributeRx platform delivered 84,000 prescriptions, representing a 120% increase compared with the corresponding period. The company also reported that its new automated Lexington facility remained on track to open in early 2027. These developments highlight activity in specialty medicines, women's healthcare and pharmaceutical distribution.

October 2026: Australian pharmaceutical industry calls for stronger investment in paediatric cancer clinical trials. Medicines Australia released a white paper outlining reforms to improve access to clinical trials for children with cancer. Although Australia secures approximately 5% of global industry-sponsored adult oncology trials, only seven industry-sponsored paediatric oncology trials were active in the country during the 12 months to June 2026. Furthermore, 75% of Australian paediatric oncology trials were not industry-sponsored. The proposed measures focus on improving regulatory and reimbursement processes, strengthening research infrastructure, encouraging investment and improving patient recruitment.

September 2026: Viral Vector Manufacturing Facility receives TGA manufacturing licence. Sydney-based Viral Vector Manufacturing Facility (VVMF) received a Therapeutic Goods Administration manufacturing licence for its Westmead facility. The approval allows the company to manufacture viral vectors under Good Manufacturing Practice conditions, including products used in advanced therapies and gene-based treatments. The licence covers manufacturing of replication-incompetent viral vectors, sterile active pharmaceutical ingredients and sterile medicinal products, alongside quality-control testing. This development strengthens Australia's domestic capabilities in advanced pharmaceutical manufacturing and cell and gene therapy supply chains.

September 2026: Medicines Australia proposes doubling investment in innovative medicines. Medicines Australia released its Access Unlocked report, calling for the Australian Government to double investment in innovative medicines as a proportion of GDP over the next decade. The industry body highlighted challenges involving reimbursement processes, medicine pricing and delays in listing new treatments under the PBS. The proposals aim to improve access to innovative therapies, strengthen Australia's competitiveness in pharmaceutical investment and encourage greater availability of advanced medicines for patients.

Key Aspects Required for the Australia Pharmaceutical Market

• Market Performance: The market increased from USD 25.3 Billion in 2025 to USD 26.2 Billion in 2026 and is projected to reach USD 31.9 Billion by 2034, driven by PBS expansion, an aging population, and government support.
• Market Outlook: A 2.50% CAGR during 2026-2034 reflects steady growth supported by biosimilar uptake, digital health integration, 60-day dispensing, and pharmacist prescribing expansion.
• Growth Drivers: Aging population and rising chronic disease burden; Commonwealth Budget healthcare investment and PBS expansion; and TGA regulatory modernization and digital health integration, together shaping long-term demand.
• Competitive Landscape: Multinationals including AbbVie, Amgen, AstraZeneca, CSL, Eli Lilly, GSK, Merck KGaA, Novartis, Pfizer, Roche, and Sanofi are competing on PBS reimbursement expertise, evidence generation, and supply chain resilience.
• Value Chain Analysis: The value chain runs from research, API sourcing, and manufacturing through TGA registration and PBAC and PBS listing to hospital, community pharmacy, and online dispensing for prescription and OTC patients across Australian regions.
• Industry Trends: Expansion of oncology biologics on the PBS; growth of electronic prescriptions and e-pharmacies; accelerating biosimilar adoption; and domestic API manufacturing investment.
• Strategic Recommendations: Strengthen PBS reimbursement and pharmacoeconomic capability; invest in biosimilar and generic portfolios; build resilient and onshore supply chains; and expand digital and community pharmacy channels.

Note: If you need any specific information that is not covered currently within the scope of the report, we will provide the same as a part of customization.

Speak to an analyst: https://www.imarcgroup.com/request?type=report&id=21978&flag=C

Frequently Asked Questions

1. What is the size of the Australia pharmaceutical market?
The market increased from USD 25.3 Billion in 2025 to USD 26.2 Billion in 2026 and is projected to reach USD 31.9 Billion by 2034.

2. What is the expected growth rate of the Australia pharmaceutical market?
The market is projected to grow at a CAGR of 2.50% during 2026-2034.

3. What is driving the growth of the Australia pharmaceutical market?
Growth is driven by PBS expansion for high-cost oncology biologics, a rapidly aging population, government healthcare investment, TGA regulatory modernization, and growing digital health adoption.